Education
About Us
Working with TipRanks
Follow Us
Incyte (INCY)
:INCY
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$50.35 - $83.95
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.94M
Market Cap
$11.73B
Enterprise Value$11.54B
Total Cash (Recent Filing)$404.75M
Total Debt (Recent Filing)$277.70M
Price to Earnings (P/E)223.5
Beta0.82
Next Earnings
May 06, 2025EPS Estimate
1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding193,524,350
10 Day Avg. Volume2,698,647
30 Day Avg. Volume1,943,987
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.83
Price to Cash Flow (P/CF)7.90
P/FCF Ratio8.20
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.94
Enterprise Value/Ebitda43.74
Forecast
1Y Price Target
$75.07Price Target Upside23.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPovorcitinib demonstrated a statistically significant difference in HiSCR50 against placebo in both trials, indicating its efficacy in treating moderate/severe hidradenitis suppurativa.
Drug ApprovalPovorcitinib could become the first oral selective JAK1 inhibitor approved in hidradenitis suppurativa, offering a new treatment option in the post-biologic setting.
Bears Say
Competitive DisadvantageBiologics offer a cleaner safety profile without any black box warnings, which could be a competitive disadvantage for povorcitinib as a JAK inhibitor.
Pipeline ProjectionsBased on the PhIII HS results, pipeline projections for Incyte are lowered, affecting the peak pipeline contribution estimate.
---
Ownership Overview
15.68% Insiders
22.48% Mutual Funds
0.42% Other Institutional Investors
36.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INCY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $50.35 and its highest was $83.95 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is $11.73B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is May 06, 2025 which is in 35 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Feb 10, 2025. The company reported $1.426 earnings per share for the quarter, missing the consensus estimate of $1.502 by -$0.076.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.04.
How many shares outstanding does Incyte have?
Incyte has 193,524,350 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of $1.426 in its last earnings report, missing expectations of $1.502. Following the earnings report the stock price went down -7.865%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in INCY
---
Incyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$75.07 (23.88% Upside)
$75.07 (23.88% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 75.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.37%
12-Months-Change
Fundamentals
Return on Equity
0.76%
Trailing 12-Months
Asset Growth
-19.64%
Trailing 12-Months
Company Description
Incyte
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
---
INCY Company Deck
---
INCY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth driven by products like Jakafi and Opzelura, significant progress in the pipeline with multiple FDA approvals, and a healthy financial position. However, challenges such as Medicare Part D dynamics, increased operating expenses, and potential pricing pressures were noted.Read More>---
INCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
---
INCY Stock 12 Month Forecast
Average Price Target
$75.07
▲(23.88% Upside)
Technical Analysis
Best Analysts Covering INCY
1 Year
1 Year Success Rate
14/22 ratings generated profit
1 Year Average Return
+3.11%
reiterated a buy rating 8 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +3.11% per trade.
---